Amid a glob­al build­out, Cy­ti­va ac­quires a provider of vi­ral vec­tor man­u­fac­tur­ing tech­nolo­gies

The life sci­ence man­u­fac­tur­er Cy­ti­va has been grow­ing its foot­print across the globe this year, but its lat­est move will see it boost its at­ten­tion to­ward the tech­nol­o­gy for mak­ing cell ther­a­pies.

Cy­ti­va has ac­quired CEVEC Phar­ma­ceu­ti­cals, a Cologne, Ger­many-based com­pa­ny cen­tered on cell line de­vel­op­ment and tech for the man­u­fac­tur­ing of vi­ral vec­tors.

In an in­ter­view with End­points News, Cy­ti­va’s pres­i­dent for ge­nom­ic med­i­cine Em­manuel Abate said that the com­pa­ny has been work­ing with CEVEC for sev­er­al years and has been watch­ing its tech­nol­o­gy de­vel­op. And while Cy­ti­va has been work­ing to make cell ther­a­pies, Abate be­lieves that there can be more im­prove­ment on the bi­ol­o­gy side and the cell lines:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER